| Holding | Rating | % Fund |
|---|---|---|
| Morgan Stanley | A | 1.3% |
| AbbVie | A | 1.2% |
| United States Government | AAA | 1.2% |
| Smb Private Education Loan Trust 2024-a | BBB | 1.1% |
| Bristol-Myers Squibb | A | 1.0% |
| Holding | Rating | % Fund |
|---|---|---|
| Goldman Sachs | A | 1.0% |
| Teva | BB | 0.9% |
| Amgen | BBB | 0.9% |
| JPMorgan Chase | AA | 0.9% |
| Freddie Mac - Stacr_20-dna4 | B | 0.8% |
| Asset type | % Fund |
|---|---|
| Other | 1.8% |
| Cash & Equivalent | 6.9% |
| Corporate Not Rated | 0.0% |
| Emerging Markets | 12.6% |
| High Yield | 31.6% |
| BB | 18.0% |
| B | 11.2% |
| CCC & below | 2.4% |
| Investment Grade Corporates | 31.6% |
| Securitized | 15.5% |
| Name | % Fund |
|---|---|
| United States | 73.5% |
| United Kingdom | 1.9% |
| Mexico | 1.7% |
| Brazil | 1.5% |
| Canada | 1.2% |
| Other | 13.3% |
| Cash & equivalents | 6.9% |